Nov. 6 at 6:47 PM
Solid Biosciences shares rose after the company announced that its investigational gene therapy for Duchenne muscular dystrophy, SGT-003, received an Innovation Passport under the UK’s Innovative Licensing and Access Pathway (ILAP).
The designation, aimed at accelerating patient access to new medicines, gives Solid enhanced regulatory support and tools to streamline development. SGT-003 is one of the first three therapies accepted into ILAP, which targets transformative treatments for unmet medical needs.
“Receiving the Innovation Passport highlights SGT-003’s potential to transform Duchenne treatment,” said Jessie Hanrahan, Chief Regulatory and Preclinical Operations Officer.
The therapy is being tested in the Phase 1/2 INSPIRE DUCHENNE trial across sites in the U.S., UK, Italy, and Canada, and in the Phase 3 IMPACT DUCHENNE trial outside the U.S.
$SLDB